Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. (Q42636572)
Jump to navigation
Jump to search
scientific article published on October 2007
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. |
scientific article published on October 2007 |
Statements
Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury (English)
Piero Ruggenenti
Dario Cattaneo
Marina Noris
Norberto Perico
Eliana Gotti
Flavio Gaspari
Elena Gagliardini
Sara Conti
Marta Todeschini
Federica Casiraghi
Vivette D'Agati
1 October 2007